CJC-1295 paired with Ipamorelin is one of the most-cited growth hormone secretagogue combinations in the research-peptide space — and unusually for this site, part of the reason is that a piece of the mechanism has actually been tested in humans, not just animal models.
Understanding Each Compound
CJC-1295 (with DAC)
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) modification extends its half-life from minutes to approximately 6–8 days by binding to serum albumin, producing sustained elevation of baseline GH and IGF-1 rather than sharp pulses.
Ipamorelin
Ipamorelin is a synthetic pentapeptide and selective agonist at the ghrelin receptor (GHSR-1a) in the pituitary. Its foundational 1998 characterization established it as the first selective GH secretagogue — stimulating GH release without significantly elevating cortisol, ACTH, or prolactin, unlike earlier GHRPs (GHRP-2, GHRP-6), which do raise cortisol and ACTH.
Why the Combination Works
CJC-1295 and Ipamorelin act on two distinct receptor systems in the GH axis — the GHRH receptor and the ghrelin receptor, respectively. Human studies of ghrelin combined with GHRH found the two peptides stimulate GH release synergistically: the combined GH response exceeded the sum of each peptide's individual response. Mechanistic work on the pituitary receptors found GHRH increases the ghrelin receptor's binding capacity in a dose-dependent way (positive binding cooperativity), and that GH secretagogues potentiate GHRH-induced cAMP production at the cellular level — a plausible molecular basis for the synergy seen in human dosing studies.
- CJC-1295 raises the baseline of GH secretion via sustained GHRH-receptor activation
- Ipamorelin activates the separate ghrelin-receptor pathway, selectively, without cortisol/ACTH elevation
- Human ghrelin+GHRH dosing studies found the combined GH response exceeds either peptide's individual response
- A human trial of CJC-1295 alone found sustained, dose-dependent GH and IGF-I increases at 30–60 mcg/kg, safe and well tolerated
The human data above is for the individual mechanisms (CJC-1295 alone; ghrelin+GHRH synergy) — there is no published human trial of the specific CJC-1295+Ipamorelin combination as sold by research vendors. The synergy mechanism is human-validated; the specific stack is not.
What the Broader Research Shows
- Increased lean body mass in animal models of sustained GH/IGF-1 elevation
- Reduction in adipose tissue, particularly visceral fat, in animal models
- Improved sleep quality reported in connection with GH's role in slow-wave sleep
- Enhanced recovery from exercise-induced muscle damage in preclinical studies
CJC-1295 and Ipamorelin are research compounds only. Neither has been approved by the FDA for human use. The lean-mass, fat-reduction, and recovery findings above are from preclinical models, not human trials.
Where to Source CJC-1295 / Ipamorelin for Research
For legitimate research applications, purity and accurate dosing are critical. We only list vendors who provide third-party HPLC testing and batch-specific Certificates of Analysis.
View the CJC-1295 / Ipamorelin product page →Frequently Asked Questions
Is there human evidence for CJC-1295 and Ipamorelin, or is it all animal studies?
Partial. CJC-1295 alone has a published human dosing trial showing sustained, dose-dependent GH/IGF-1 increases. The GHRH+ghrelin synergy mechanism has also been demonstrated in humans. But the specific combination product sold by research vendors has not itself been through a published human trial — the lean-mass and fat-reduction findings for the stack specifically are animal-model data.
Why doesn't Ipamorelin raise cortisol like older GH secretagogues?
Its original 1998 characterization found it selectively activates the ghrelin receptor pathway for GH release without the cross-activity on ACTH/cortisol pathways seen with older GHRPs like GHRP-6 and GHRP-2 — a deliberate selectivity improvement, not an accident of dosing.
References
1. Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." PubMed
2. Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." PubMed
3. "A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans." PubMed
4. "Ghrelin and Growth Hormone (GH) Secretagogues Potentiate GH-Releasing Hormone (GHRH)-Induced Cyclic AMP Production..." PubMed
This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.